Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology ...

ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced ...

Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband (NTRB) is targeting to file for FDA approval for AVERSA™ ...

Expands Global Intellectual Property Portfolio Supporting Long-Term Revenue Growth VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / Ovation Science Inc. (CSE:OVAT)(OTC PINK:OVATF) ("Ovation" or the ...

Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid ...

Love Pharma has struck a deal to acquire transdermal drug delivery technology, signing a letter of intent to buy Naltrexone Therapeutics for intellectual property covering the administration of a ...

Nutriband Inc. announced it has received a Notice of Allowance from the USPTO for its patent application regarding the Aversa™ abuse deterrent technology, which is designed to prevent the misuse and ...